Drug has worked extremely well in myeloproliferative neoplasm called myelofibrosis of which there were about 18,000 known patients in the United States. It treats the very debilitating symptoms of the disease and also as part of that shrinks the very large spleens that many of these patients get. There is accumulating data that shows that the drug may well prolong survival, although we don’t have that in the label. And the drug was approved for use in intermediate and high-risk patients which comprise about 85% of that 18,000, and without any restriction on platelet count, despite the fact that we had only studied patients with platelet counts above 100,000 in our Phase III studies.So the approval was towards the end of last year, and our revenue is growing in a steady and sustained way. And we are getting reports back from the field and from physicians that they are seeing pretty dramatic effects which is the same thing we saw in the Phase III studies.
Incyte's CEO Presents At Morgan Stanley Healthcare Conference (Transcript)
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.